Johnson & Johnson saw growth in its third-quarter orthopedic and total sales, according to financial results posted Oct. 14.
Seven things to know:
1. Orthopedic sales were $2.3 billion, an increase of 3.8% compared to the same period in 2024.
2. Hip sales grew 6.4% year over year with $405 million, and knee sales grew 7% year over year with $377 million.
3. Trauma sales increased 4.2% year over year with $793 million.
4. Spine, sports and other sales were $698 million, a less than one percent increase year over year.
5. Johnson & Johnson’s orthopedic gains come amid news that it is splitting off DePuy Synthes into its own company.
6. Full-quarter revenue was $24 billion, an increase of 6.8% year over year.
7. The company increased its full-year guidance to $93.7 billion.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
